The impact of surgical strategy and rifampin on treatment outcome in Cutibacterium periprosthetic joint infections by Achermann, Yvonne et al.








The impact of surgical strategy and rifampin on treatment outcome in
Cutibacterium periprosthetic joint infections
Achermann, Yvonne ; Kusejko, Katharina ; Auñón, Álvaro ; Clauss, Martin ; Corvec, Stéphane ;
Esteban, Jaime ; Fernandez-Sampedro, Marta ; Ferrari, Matteo Carlo ; Gassmann, Natalie ; Jent,
Philipp ; Jost, Bernhard ; Kouyos, Roger D ; Kramer, Tobias Siegfried ; Lora-Tamayo, Jaime ; Morand,
Philippe C ; Benito, Natividad ; Pablo-Marcos, Daniel ; Patel, Robin ; Scanferla, Giulia ; Sendi,
Parham ; Slama, Dorsaf ; Stadelmann, Vincent A ; Strahm, Carol ; Thurnheer, Christine ; Trebše,
Rihard ; Uckay, Ilker ; Vijayvargiya, Prakhar ; Waldmann, Isabelle ; Wouthuyzen-Bakker, Marjan
Abstract: BACKGROUND Cutibacterium species are common pathogens in periprosthetic joint infec-
tions (PJI). These infections are often treated with ฀-lactams or clindamycin as monotherapy, or in
combination with rifampin. Clinical evidence supporting the value of adding rifampin for treatment of
Cutibacterium PJI is lacking. MATERIALS/METHODS In this multicenter retrospective study, we
evaluated patients with Cutibacterium PJI. The primary endpoint was clinical success, defined by the
absence of infection relapse or new infection within a minimal follow-up of 12 months. We used Fisher’s
exact tests and Cox proportional hazards models to analyze the effect of rifampin and other factors on
clinical success after PJI. RESULTS We included 187 patients (72.2% male, median age 67 years) with
a median follow-up of 36 months. The surgical intervention was two-stage exchange in 95 (50.8%), one-
stage exchange in 51 (27.3%), debridement and implant retention (DAIR) in 34 (18.2%), and explantation
without reimplantation in 7 (3.7%). Rifampin was included in the antibiotic regimen in 81 (43.3%) cases.
Infection relapse occurred in 28 (15.0%), and new infection in 13 (7.0%) cases. In the time-to-event
analysis, DAIR (adjusted HR=2.15, p=0.03) and antibiotic treatment over 6 weeks (adjusted HR=0.29,
p=0.0002) significantly influenced treatment failure. We observed a tentative evidence for a beneficial
effect of adding rifampin to the antibiotic treatment - though not statistically significant for treatment
failure (adjusted HR=0.5, p=0.07) and not for relapses (adjusted HR=0.5, p=0.10). CONCLUSIONS
We conclude that a rifampin combination is not markedly superior in Cutibacterium PJI but a dedicated
prospective multicenter study is needed.
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Summary. In this retrospective study, we observed no significant benefit of using rifampin to 
avoid relapses or new infections but a benefit when the prosthesis was removed or 










































































































Background: Cutibacterium species are common pathogens in periprosthetic joint infections 
(PJI). These infections are often treated with -lactams or clindamycin as monotherapy, or in 
combination with rifampin. Clinical evidence supporting the value of adding rifampin for 
treatment of Cutibacterium PJI is lacking. 
Materials/methods: In this multicenter retrospective study, we evaluated patients with 
Cutibacterium PJI. The primary endpoint was clinical success, defined by the absence of 
infection relapse or new infection within a minimal follow-up of 12 months. We used Fisher’s 
exact tests and Cox proportional hazards models to analyze the effect of rifampin and other 
factors on clinical success after PJI. 
Results: We included 187 patients (72.2% male, median age 67 years) with a median follow-
up of 36 months. The surgical intervention was two-stage exchange in 95 (50.8%), one-stage 
exchange in 51 (27.3%), debridement and implant retention (DAIR) in 34 (18.2%), and 
explantation without reimplantation in 7 (3.7%). Rifampin was included in the antibiotic 
regimen in 81 (43.3%) cases. Infection relapse occurred in 28 (15.0%), and new infection in 
13 (7.0%) cases. In the time-to-event analysis, DAIR (adjusted HR=2.15, p=0.03) and 
antibiotic treatment over 6 weeks (adjusted HR=0.29, p=0.0002) significantly influenced 
treatment failure. We observed a tentative evidence for a beneficial effect of adding rifampin 
to the antibiotic treatment – though not statistically significant for treatment failure (adjusted 
HR=0.5, p=0.07) and not for relapses (adjusted HR=0.5, p=0.10). 
Conclusions: We conclude that a rifampin combination is not markedly superior in 
Cutibacterium PJI but a dedicated prospective multicenter study is needed.  
Keywords. Cutibacterium species, Propionibacterium species, Periprosthetic joint infections, 










































































































Cutibacterium species (mainly Cutibacterium acnes and Cutibacterium avidum), are, after 
staphylococci and streptococci, amongst the most frequently isolated pathogens causing 
periprosthetic joint infections (PJIs) (1). C. acnes predominantly infects shoulder and hip 
implants (2), whereas C. avidum is associated with hip arthroplasty infection (3–6). In 
general, PJIs are difficult to cure since bacteria grow as biofilms on implants. In biofilms,  the 
sessile bacteria are embedded in a matrix of extracellular polymeric substances, which are at 
least partially produced by the bacteria themselves; bacteria in biofilms are protected against 
the immune system (7,8). Sessile bacteria have a low metabolism and consequently 
replicate at a slow rate (7).  
Rifampin has a low minimal bactericidal concentration (MIC) against sessile Staphylococcus 
aureus and coagulase-negative staphylococci (9). Accordingly, rifampin has been shown to 
cure experimental implant-associated staphylococcal infections in animal models and 
combination with rifampin has been found to be more efficacious than standard therapy in 
observational studies as well as in a controlled trial of patients with orthopedic device-
associated infection managed with debridement and retention of prosthesis (DAIR) (10–14). 
In analogy to treatment concepts for staphylococcal infections, antibiotic regimens including 
rifampin are used to treat Cutibacterium PJIs in some orthopedic centers due to low MIC. In 
small case series, rifampin was combined with clindamycin (15,16) or amoxicillin (17). There 
are, however, some suggestions that support adding rifampin in the treatment of 
Cutibacterium infections. Furustrand et al. showed in a guinea pig model that antibiotic 
regimens containing rifampin in Cutibacterium infections yielded favorable results when an 
implant is present (18). Rifampin cured 63% of the infected cages in combination with 
daptomycin, 46% with vancomycin, and 25% with levofloxacin whereas monotherapy with 
daptomycin, vancomycin, or levofloxacin cured only 4%, 17%, and 0% of infections, 
respectively. Thus, combinations with rifampin were superior to single regimens without 








































































































large study evaluating rifampin in humans is available. Due to the lack of large clinical 
studies, it is unclear if addition of rifampin is indeed necessary for cure of Cutibacterium PJI.   
In a large cohort of patients with Cutibacterium PJI, we tested the hypothesis that 
adding rifampin to an antibiotic regimen for cure of infection is not superior to antibiotic 
regimen without rifampin. Moreover, we hypothesized that the choice of surgical treatment 
concept is a major element determining successful outcome of these infections.  
Methods 
Study setting and population 
 This is a multicenter retrospective study including patients from 9 countries (18 
centers) with a PJI diagnosis between 2005 and 2018. We evaluated patients with 
Cutibacterium PJI, defined by growth of Cutibacterium acnes, Cutibacterium avidum, or 
Cutibacterium granulosum from at least two different diagnostic samples including tissue 
biopsies, sonication fluid, or synovial fluid. Samples for microbiology were cultivated for 14 
days in 13/18 (72.2%) and 6-10 days in 5/18 (27.8%) of the study centers. We recorded 
information about clinical presentation, antibiotic and surgical treatment, and infection 
outcome. The case report form (CRF) relies on the PJI database app developed by the study 
group ESGIAI supported by ESCHMID (https://apps.apple.com/us/app/pji-
database/id1331588615). We only included patients who underwent surgery for curative 
management of Cutibacterium PJI, i.e., one-stage or two-stage exchange of the prosthesis 
(with or without spacer implantation), DAIR, or explantation without new prosthesis. Patients 
were followed until infection relapse, new infection or death with a minimum follow-up of 12 
months after the surgical intervention for Cutibacterium PJI. We did not include cases with 
only one positive Cutibacterium sample but treated as infection, polymicrobial infection, an 
antibiotic treatment longer than 6 months or labelled as lifelong suppressive treatment, no 










































































































 We distinguished between early acute infections with time to septic surgery less than 
4 weeks after last surgery and chronic infections with time to septic surgery longer than 4 
weeks. The primary endpoint of our study was treatment failure, defined as either infection 
relapse, new infection or death due to PJI. Infection relapse was defined as proven, when 
persisting signs or symptoms of infection (pain, swelling, redness, wound secretion, or 
elevated serum inflammatory parameters) were present and two new diagnostic samples 
microbiologically identified the same Cutibacterium species. We defined it as possible, when 
not microbiologically proven but suggested by persisting symptoms or signs of infection. A 
new infection was defined as a microbiologically proven infection in case of a new pathogen 
detected in ≥2 diagnostic samples during the follow-up time. The follow-up time started at the 
date of the initial surgery for Cutibacterium PJI, specifically, the date of explantation in case 
of a two-stage exchange of the prosthesis. 
Antibiotic treatment 
 Patients were grouped into a rifampin-group in case rifampin was used after the 
surgery for Cutibacterium PJI for at least one week, with a sensitivity analysis using the 
thresholds of at least 4 weeks and at least 6 weeks. Antibiotic treatment duration was 
calculated as the total duration for all drugs (including rifampin) combined, as well as for 
intravenous (iv), per oral (po), and rifampin use.  
Statistical Analyses 
 Patient characteristics between the group of patients who received rifampin and those 
who did not receive rifampin were analyzed using t-tests (continuous variables) and chi-
squared tests (categorical variables). The effect of adding rifampin to the antibiotic regimen 
on clinical success was tested in two ways, cross-sectionally as well as longitudinally (time to 
treatment failure): First, a cross-sectional analysis (chi-squared test) was used to analyze the 








































































































strategy. Second, the time to treatment failure and time to relapse was assessed using cox 
proportional hazards models, with explanatory variables including rifampin as well as the 
most important demographic and clinical parameters. Proportional hazards assumptions 
were analyzed using Schoenfeld residuals available in the R package survival (19). Models 
were adjusted for total duration of antibiotic use as well as the surgical strategy, i.e., the two 
clinically most relevant factors. To assess the effect of the treatment center, we performed a 
sensitivity analysis using a mixed effect model, where the country was included as a random 
effect. Statistical analyses were performed using R (version 3.4.4). Moreover, to assess the 
effect of the most commonly used treatment regimen in literature (clindamycin/rifampin), we 
performed a sensitivity analysis in which we looked at hazard ratios of other rifampin 
combinations than clindamycin, clindamycin alone, and other monotreatment.  
Results 
Study Population 
 We included 187 patients from 9 countries, the median time of follow-up after 
infection treatment was 36 months. Most patients were male (72.2%) with a median age of 
67 years and a median BMI of 28 kg/m2 (Table 1). The median time to PJI after the last 
surgical procedure was 20 months, with a chronic infection (> 1 month) in 177 (94.7%) 
patients and early postoperative infection (< 1 month) in 10 (5.3%). All but one had a 
treatment failure in the late postoperative phase. The one patient with an early postoperative 
treatment failure had a new infection (Supplementary Table S1). The most common joint 
prostheses were hip (51.9%), shoulder (37.3%) and knee (9.1%). In most cases, the isolated 
pathogen in two or more diagnostic samples was C. acnes (84.5%) (Table 1). 
Two-stage exchange of the prosthesis was performed in 95 (50.8%), one-stage exchange of 
the prosthesis in 51 (27.3%) and DAIR in 34 (18.2%) patients (see Table S1 for the surgical 
strategy in acute versus chronic cases). The median overall antibiotic duration was 12 








































































































Most patients (174, 93.0%) were prescribed iv antibiotics. Rifampin was prescribed in 81 
(43.3%) cases, the median duration of rifampin use was 10 weeks (Table 2 and Figure S1). 
Rifampin 
 There were no significant differences regarding gender, age, BMI and the involved 
joint prosthesis between patients who received rifampin and those who did not. There was, 
however, a difference regarding the surgical strategy: While one-stage exchange of 
prosthesis was performed in 31/81 (38.3%) and two-stage exchange in 32/81 (39.5%) of 
patients who received rifampin, this was the case in 20/106 (18.9%) and 63/106 (59.4%) of 
patients who did not receive rifampin, respectively, (p = 0.037).  
We also saw differences in the countries in which the patients were treated, ranging between 
no patients and more than half patients receiving rifampin (Table S2). Moreover, there was 
no clear time trend in prescribing rifampin during the study time frame (Figure S2). Overall, 
follow-up time and the overall antibiotic duration was longer in patients who received rifampin 
compared to those who did, for all antibiotics combined or iv or po antibiotics separately 
(Table 2). The combination treatment with rifampin is documented in Supplementary Table 
S3. 
Outcome 
 Overall, treatment failure (relapse and new infection) manifested in 38 (20.3%) cases. 
Infection relapses occurred in 28 (15.0%) cases (proven relapse: 16, possible relapse: 12), 
and new infection in 13 (7.0%). During follow-up, 13 (7.0%) patients died, PJI did not result in 
death (Table 2). Among the patients treated with rifampin, treatment failure was observed in 
10 (12.3%) cases, as compared to 28 (26.4%) cases among patients not treated with 
rifampin (p = 0.029). This difference was however not significant for relapse and new 
infection separately, which was observed in 8 (9.9%) and 2 (2.5%) cases of patients who 
received rifampin, respectively, compared to 20 (18.9%) and 11 (10.4%) cases in patients 








































































































by surgical strategy, the frequency of treatment failures was highest in patients for whom 
DAIR was performed (11/34, 32.4%), as compared to one-stage (6/51, 11.7%) or two-stage 
exchange (20/95, 21.1%) of prosthesis. In each group (DAIR, one-stage exchange, two-
stage exchange), fewer treatment failures in patients who received rifampin were observed. 
This difference was not significant looking cross-sectionally at overall treatment failures of 
relapses only (Figure 1). In a sensitivity analysis, we restricted to the first 3 years after 
surgical intervention with no significant difference either (see Figure S3). 
Dynamic of failure overall and relapse 
The median time to treatment failure was 19.3 months (IQR = 7.0 – 58.1) (Figure 
2A). We observed increased hazards of treatment failure in patients not treated with rifampin 
as compared to patients treated with rifampin (unadjusted hazard ratio (HR) = 2.50 CI = 
[1.21, 5.16], p = 0.013, Figure 2B) as well as increased hazards of treatment failure in 
patients who underwent DAIR as compared to one-stage exchange (unadjusted HR = 3.4 
[1.26, 9.27], p = 0.016) or two-stage exchange (unadjusted HR = 1.6 [0.78, 3.42], p = 0.19) of 
prosthesis (Figure 2C).  
The median time to infection relapse was 23.3 months (IQR = 8.6 – 60.5) (Figure 
2D). Again, increased hazards of infection relapse were observed in patients who did not 
receive rifampin (unadjusted HR = 2.28 [1.00, 5.18], p = 0.05) (Figure 2E) and patients who 
underwent DAIR as compared to one-stage exchange (HR = 3.08 [1.0, 9.52], p = 0.05) or 
two-stage exchange (HR = 1.76 [0.74, 4.23], p = 0.20) of prosthesis (Figure 2F). The median 
time to new infection was 11.4 months (IQR = 6.8 – 39.1). 
Effect of rifampin and other factors  
 The effect of adding rifampin to the antibiotic combination therapy was not significant 
after adjusting for surgical strategy and overall duration of antibiotic treatment (adjusted HR: 
0.50 [0.23, 1.05], p = 0.07) (Figure 3A). However, using DAIR instead of a surgical strategy 








































































































treatment failure, even after adjusting for antibiotic duration (HR: 2.15 [1.06, 4.37], p = 0.03). 
Moreover, an overall antibiotic duration of more than 6 weeks was associated with a reduced 
hazard for treatment failure even after adjusting for surgical strategy (adjusted HR: 0.29 
[0.15, 0.56], p = 0.0002). Similar results were obtained for relapse only (Figure 3B). In a 
sensitivity analysis, we only grouped patients into the rifampin stratum in case the intake 
lasted at least 4 or 6 weeks, respectively, and obtained similar results (Table S4). Most 
patients included in this study came from one country (n = 105) (country 1, Table 1) but the 
rate of rifampin strongly differed between countries. Therefore, we used a mixed effects 
model to include the effect of different countries, again leading to similar results (Figure S4). 
Due to the heterogeneity of our study population with different antibiotic regimens (Table S3), 
we did not stratify treatment outcome for all different antibiotic regimens. However, in a 
sensitivity analysis, success rate was highest for the combination with rifampin and 
clindamycin, although the difference was not statistically significant (Table S3 and Figure 
S5). 
Discussion 
 In this multicenter study, we included 187 patients with Cutibacterium PJI and 
evaluated the added value of rifampin as part of antibiotic regimens following septic surgery. 
We observed an overall successful treatment outcome in 79.7% cases, with relapses in 15% 
and new infection in 7% cases. We observed a tentative evidence for a beneficial effect of 
adding rifampin to the antibiotic treatment – though not statistically significant, the hazards 
for developing treatment failure was halved in the group of patients treated with rifampin. A 
statistically significant effect halving the hazards of developing treatment failure was 
observed for choosing the exchange of the prosthesis instead of DAIR to successfully 
treating Cutibacterium PJI and an antibiotic treatment of at least 6 weeks.  
In this largest case series up to now on Cutibacterium PJI, we show that clinical 
success is mainly dominated by performing a surgical approach with removal or exchange of 








































































































Zimmerli et al. (20) and treatment outcome studies (21–24) is the proper selection of patients 
for DAIR to achieve high clinical success. Barberan et al. showed in 60 staphylococcal PJI 
(25) that the treatment success rate with a DAIR regimen decreased from 83.4% when 
symptoms were less than month to 65.2% when between 2 and 6 months and to 30.8% 
when more than 6 months of symptoms. We counted a chronic infection in 94.7% with a 
median time to infection of 11.4 months in which an exchange of the prosthesis should be 
performed due to mature biofilm. However, a DAIR without removal of the implant approach 
was chosen in a higher proportion of the patients with 18.2% even though some of these 
patients had a chronic infection. Looking at patients with an exchange of the prostheses, we 
observed less treatment failures when performing one-stage exchange as compared to two-
stage exchange (Figure 1). Despite the reduced risk for the patients by having only one 
operation instead of two operations, one-stage exchange is so far rarely the concept of 
choice. However, several studies highlighted the good clinical outcome of one-stage 
exchange (26–29). 
We observed an overall treatment success rate of 80% and 85% when only looking at 
relapses, which was not significantly different in patients treated with rifampin versus those 
without (89.9% versus 81.5%). This is in line with the study by Jacobs et al. (15) analyzing 60 
patients with Cutibacterium PJI and observing an overall success rate of 86% after 2 years 
follow-up and no significant difference between clindamycin/rifampin versus clindamycin 
alone. However, caution is needed when prescribing rifampin in combination antibiotic 
therapy. Besides several known side effects of rifampin (e.g. nausea, hepatitis) and drug 
interactions, emergence of resistance to rifampin is a complication when used in 
staphylococcal infections (30). There are a few reports also describing rifampin resistance in 
Cutibacteria (31–34). Since Cutibacterium isolates from relapse cases were not stored as a 
routine, we could not determine whether emergence of resistance is a relevant problem in 








































































































Besides the chosen surgical strategy, the length of antibiotic treatment was an 
important factor for clinical success in our study. We found that antibiotic regimens of more 
than six weeks were superior to regimens less than six weeks which we interpreted as a 
need for treating biofilm infections. IDSA guidelines also recommend an antibiotic treatment 
of at least 6 weeks (35). Compared to the success rate of 86% in the paper of Jacobs et al 
(15) with 60 Cutibacterium PJI, our lower success rate of 79% overall could be due to the 
treatment of less than 6 weeks in 7.5% (14 out of 187) of the cases. We did not detect any 
difference between intravenous antibiotic duration of more or less than 14 days. An 
intravenous treatment of 2-4 weeks to treat PJIs was suggested in the review article by 
Zimmerli et al. in 2004 (20) with the rationale of a better bone penetration with intravenous 
antibiotics (36). In line with our results, a benefit of iv treatment longer than 7 days was not 
shown in the recently published OVIVA trial (37,38).  
 This study has several strengths and limitations. A strength is that we were able to 
include a large number of cases from different countries, with in-depth patient and clinical 
information, with a curative treatment regimen, and a long follow-up time. Gathering data 
from different centers increases the risk of different ways of data management, hence a 
center bias in our results cannot be excluded. We included a sensitivity analysis where we 
performed a mixed effects approach including the center as random effect. Moreover, due to 
the retrospective nature of this project – as compared to a prospective clinical trial – optimal 
data quality cannot be guaranteed, included missing information. However, huge efforts were 
taken to clean the data and retrospectively get information about missing and inconsistent 
data, leading to good quality in the main outcome variables. One limitation concerns the 
definition of infection relapse. First, we included not only microbiologically proven relapses 
but also probable relapses. Second, we included relapses happening more than 2 years after 
septic surgery. It could be the case that these relapses are actually new infections with 
another Cutibacterium isolate, which is not distinguishable without characterizing the 
isolates. To overcome this problem, we concentrated on analyzing clinical success, i.e., 








































































































 We conclude that a rifampin combination is not markedly superior, although 
considering the mixed data both in the literature and this study's results, it is still inconclusive 
as to whether rifampin should be recommended. Hence this emphasizes the need for a 
dedicated prospective multicenter study. However, our study results suggest to insist on 
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Tables and Figures 
 
Table 1. Baseline characteristics of 187 cases treated for a Cutibacterium PJI with (n=81, 43.3%) and without (n=106, 56.7%) a rifampin 
combination. Body mass index (BMI) was defined as the weight (in kg) divided by the height (in m) squared. 
   All patients With rifampin Without rifampin 
Comparison 
(p value) 
Total   187 81 106  
General patient information        
Follow-up time months (median, IQR) 36 [23, 60] 43 [25, 70] 33 [21, 47] 0.0344 
Sex male 135/187 (72.2%) 60/81 (74.1%) 75/106 (70.8%) 0.7359 
  female 52/187 (27.8%) 21/81 (25.9%) 31/106 (29.2%)  
Age median, IQR 67 [58, 74] 65 [57, 72] 68 [59, 76] 0.1959 








































































































   All patients With rifampin Without rifampin 
Comparison 
(p value) 
Country Country 1 105/187 (56.1%) 62/81 (76.5%) 43/106 (40.6%) 0.0002 
  Country 2 28/187 (15.0%) 10/81 (12.3%) 18/106 (17.0%) 
  Country 3 19/187 (10.2%) 4/81 (4.9%) 15/106 (14.2%) 
  Country 4 13/187 (7.0%) 0/81(0.0%) 13/106 (12.3%) 
  Country 5 7/187 (3.7%) 1/81 (1.2%) 6/106 (5.7%) 
  Country 6 7/187 (3.7%) 2/81 (2.5%) 5/106 (4.7%) 
  Country 7 6/187 (3.2%) 2/81 (2.5%) 4/106 (3.8%) 
  Country 8 1/187 (0.5%) 0/81 (0.0%) 1/106 (0.9%) 
  Country 9 1/187 (0.5%) 0/81 (0.0%) 1/106 (0.9%) 








































































































   All patients With rifampin Without rifampin 
Comparison 
(p value) 
Joint prosthesis hip 97/187 (51.9%) 40/81 (49.4%) 57/106 (53.8%) 0.3501 
  shoulder 70/187 (37.4%) 34/81 (42.0%) 36/106 (34.0%) 
  knee 17/187 (9.1%) 7/81 (8.6%) 10/106 (9.4%) 
















































































































Table 2: Infection characteristics of 187 patients with a Cutibacterium PJI treated with rifampin** (n = 81) and without (n = 106) 




Total   187 81 106  
Cutibacterium species C. acnes 158/187 (84.5%) 66/81 (81.5%) 91106 (85.8%) 0.6189 
  C. avidum 20/187 (10.7%) 10/81 (12.3%) 10/106 (9.4%) 
  C. granulosum 9/187 (4.8%) 4/81 (4.9%) 5/106 (4.7%) 












































































































Total   187 81 106  
Sinus tract n, % 19/187 (10.2%) 4/81 (4.9%) 15/106 (14.2%) 0.0685 
Pain n, % 164/187 (87.7%) 67/81 (82.7%) 97/106 (91.5%) 0.1119 
Pathogenesis outcome          
Time to PJI months (median, IQR)  20 [6, 41] 20 [4, 42] 18 [8, 39] 0.1304 
Acute early (≤ 4 weeks after 
last surgery) 
n, % 10/187 (5.3%) 7/81 (8.6%) 3/106 (2.8%)  
Chronic late (> 4 weeks after 
last surgery) 
n, % 177/187 (94.7%) 74/81 (91.4%) 103/106 (97.2%)  
Antibiotic treatment          












































































































Total   187 81 106  
duration*** 
Overall duration > 6 weeks n, % 141/187 (75.4%) 69/81 (85.2%) 72/1066 (67.9%) - 
IV antibiotics duration days (median, IQR) 14 [10, 24.5] 14 [9, 18] 16 [10.2, 28] 0.0087 
IV antibiotics n, % 174/187 (93.0%) 73/81 (90.1%) 101/106 (95.3%) 0.2781 
IV duration > 14 days n, % 89/187 (47.6%) 30/81 (37.0%) 59/106 (55.7%) - 
P.O antibiotics duration weeks (median, IQR) 9 [4, 11] 10 [7, 12] 7 [4, 10] <0.0001 
Rifampin duration weeks (median, IQR)  10 [6, 12]  - 
Rifampin duration > 6 weeks n, %  58/81 (71.6%)  - 
Treatment: Surgical concept Debridement and retention of 
prosthesis (DAIR) 












































































































Total   187 81 106  
  One-stage exchange of prosthesis 51/187 (27.3%) 3181 (38.3%) 20/106 (18.9%) 
  Two-stage exchange of prosthesis with 
spacer 
63/187 (33.7%) 20/81 (24.7%) 43/106 (40.3%) 
  Two-stage exchange of prosthesis 
without spacer 
32/187 (17.1%) 12/81 (14.8%) 20/106 (18.9%) 
  Explantation without new prosthesis 7/187 (3.7%) 3/81 (3.7%) 4/106 (3.8%) 
Outcome          
Overall failure* (n, %) 38/187 (20.3%) 10/81 (12.3%) 28/106 (26.5%) 0.0288 
Relapse proven and possible (n, %) 28/187 (15.0%) 8/81 (9.9%) 20/106 (18.9%) 0.1334 












































































































Total   187 81 106  
  possible (n, %) 12/28 (42.9%) 3/8 (37.5%) 9/20 (45.0%)  
Relapse: Time of occurrence  at implantation (n, %) 11/28 (39.3%) 3/8 (37.5%) 8/20 (40.0%)  
  during AB treatment (n, %) 8/28 (28.6%) 2/8 (25.0%) 6/20 (30.0%)  
  after AB treatment stop (n, %) 9/28 (32.1%) 4/8 (50.0%) 5/20 (25.0%)  
New infection n, % 13/187 (7.0%) 2/81 (2.5%) 11/106 (10.4%) 0.0692 
New infection: Time of 
occurrence 
 at implantation (n, %) 2/13 (15.4%) 0/2 (0.0%) 2/11 (18.2%)  
   during AB treatment (n, %) 2/13 (15.4%) 0/2 (0.0%) 2/11 (18.2%)  
   after AB treatment stop (n, %) 9/13 (69.2%) 1/2 (50.0%) 8/11 (72.7%)  












































































































Total   187 81 106  
  due to PJI (n, %) 0/187 (0.0%) 0/81 (0.0%) 0/106 (0.0%)  
* Several patients had an infection relapse as well as a new infection. 
** rifampin doses were prescribed as 450mg bid in 44.4%, 600mg mid in 27.8%. In 33.3% doses was not recorded 
*** In patients treated with a two-stage exchange of prosthesis with a long interval of at least 6 weeks of antibiotic treatment followed by an 
antibiotic-free window of 2 weeks, antibiotic treatment duration was counted until the start of the antibiotic window. In those patients with a two-
stage exchange and a short first interval of antibiotic treatment, iv and po antibiotic treatment duration was combined after the explantation and the 












































































































Figure 1. Outcome of Cutibacterium PJIs stratified by surgical strategy (DAIR, one-stage exchange, two-stage exchange), either looking at failures 
in general (panel A), or at relapses only (panel B). 
 
Figure 2: A) Kaplan-Meier curve of all patients (n = 187), with 38 having treatment failure, i.e., infection relapse or new infection; B) Kaplan-Meier 
curve of patients using rifampin (n = 81, 10 failures) and not using rifampin (n = 106, 28 failures); C) Kaplan-Meier curve of patients stratified by 
surgical strategy: one-stage exchange (n = 51, 6 failures), two-stage exchange (n = 95, 20 failures), DAIR (n = 34, 11 failures); D) Kaplan-Meier 
curve of all patients (n = 187), with 28 having an infection relapse; E) Kaplan-Meier curve of patients prescribed rifampin (n = 81, 8 relapses) or not 
(n = 106, 20 relapses); F) Kaplan-Meier curve of patients stratified by surgical strategy: one-stage exchange (n = 51, 5 relapses), two-stage 
exchange (n = 95, 14 relapses), DAIR (n = 34, 8 relapses). 
 
Figure 3: Factors influencing failure overall (panel A) and relapse (panel B). PJI: periprosthetic joint infections, UV: univariable, HR: 
hazards ratio, MV: multivariable, BMI: body mass index, overweight: BMI >25, obese: BMI >30, iv: intravenous, DAIR = debridement 
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A) Factors influencing treatment failure (relapse or new infection) in patients with PJI
unadjusted adjusted: surgical strategy, total antibiotic duration
Female gender
Age (ref = < 65)
Joint (ref = hip)


















































































































































































B) Factors influencing infection relapse in patients with PJI
unadjusted adjusted: surgical strategy, total antibiotic duration
Female gender
Age (ref = < 65)
Joint (ref = hip)
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